(Total Views: 723)
Posted On: 07/30/2019 2:42:46 PM
Post# of 72447
The Alpahsigma agreement does NOT include RFR or RFN for B-OM.
7/22/19 “The agreement also includes a Right of First Refusal for Brilacidin for the treatment of more extensive forms of Inflammatory Bowel Disease (IBD), such as Ulcerative Colitis and Crohn’s Disease, and a Right of First Negotiation for Brilacidin in other Gastrointestinal indications.”
7/22/19 Pier Vincenzo Colli, Chief Executive Officer at Alfasigma. “We will also closely follow Innovation’s progress in developing oral Brilacidin, as we remain highly interested in novel oral IBD treatments.”
7/29/19 “Successfully completing additional strategic alliances and licensing deals remains a primary objective, towards which we are making notable progress, with multiple active advanced-stage negotiations ongoing.”
7/22/19 “The agreement also includes a Right of First Refusal for Brilacidin for the treatment of more extensive forms of Inflammatory Bowel Disease (IBD), such as Ulcerative Colitis and Crohn’s Disease, and a Right of First Negotiation for Brilacidin in other Gastrointestinal indications.”
7/22/19 Pier Vincenzo Colli, Chief Executive Officer at Alfasigma. “We will also closely follow Innovation’s progress in developing oral Brilacidin, as we remain highly interested in novel oral IBD treatments.”
7/29/19 “Successfully completing additional strategic alliances and licensing deals remains a primary objective, towards which we are making notable progress, with multiple active advanced-stage negotiations ongoing.”
(5)
(0)
